||Last Updated: Nov 17th, 2006 - 22:35:04
Why smokers rarely suffer from ulcerative colitis
Doctors have long known that smokers rarely suffer from a common form of inflammatory bowel disease (IBD) called ulcerative colitis, but they didn't know why. A new study in the December 19 issue of The Journal of Experimental Medicine might help explain this apparent resistance. Scott Plevy and his colleagues at the University of Pittsburgh now show that carbon monoxide (CO), a component of cigarette smoke, helps shut down the intestinal inflammation that causes ulcerative colitis.
Dec 20, 2005, 00:16
Exercise, eating right could ease IBS, diarrhea and constipation
Physical activity may help reduce gastrointestinal (GI) symptoms in people who are obese. In a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, researchers found that a high body mass index (BMI) and lack of physical activity were associated with an increase in GI symptoms such as stomach pain, diarrhea, constipation and irritable bowel syndrome (IBS).
Oct 4, 2005, 00:32
Budesonide Prolongs Remission of Crohn's Disease
In a study published in The American Journal of Gastroenterology, researchers found that budesonide capsules are an effective treatment to prolong and maintain the period of remission of Crohn’s Disease. Previous studies have demonstrated that budesonide is effective for inducing remission of Crohn’s disease.
Sep 14, 2005, 01:59
Genome wide approach to pinpoint gene activations in IBD
In a paper published in PLoS Medicine researchers from the German Genome Research Network have analysed the expression of thousands of genes from patients with inflammatory bowel disease (ulcerative colitis and Crohn disease) using a genome wide approach to produce a comprehensive picture of which genes are activated in these conditions.
Aug 23, 2005, 21:02
Certolizumab Shows Significant Benefit in Moderate to Severe Crohn’s Disease
UCB today announced significant positive results for the two pivotal phase III trials (PRECISE 1 and 2) of CIMZIATM (certolizumab pegol, CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn’s disease. The PRECiSE trials assessed the safety and efficacy of CIMZIA compared to placebo over a 26 week period, in a total of 1330 patients with active Crohn’s disease.
Jul 27, 2005, 14:11
Probiotic bacteria mixture VSL#3 ease ulcerative colitis pain
A mixture of bacteria developed in part by University of Alberta researchers has been proven highly effective in treating people suffering from ulcerative colitis.
Jul 26, 2005, 01:05
Pediatric Researchers Collaborate to Build Largest Inflammatory Bowel Disease Registry
To build the registry, Emory researchers joined others involved in the National Pediatric IBD Consortium, to collect uniform data from January 2000 to November 2003 from a cohort of 1370 young IBD patients. The results, published in an article in the January issue of the Journal of Pediatrics, show that 54 percent of IBD patients were male and 86 percent were white. The largest percentage of IBD diagnosis (48 percent) was made in children ages six to 12, and more than 63 percent of children younger than eight had isolated colonic disease -- a disease limited to the large bowel or colon. Researchers also found that 29 percent of everyone in the registry had at least one family member with IBD.
Feb 18, 2005, 17:40
Irritable bowel syndrome, frequent indigestion common in people with insomnia
Mayo Clinic researchers report in the current issue of Mayo Clinic Proceedings an association between gastrointestinal disorders and sleep disturbances. The association is important because these problems cause significant health issues including greater need for general medical and mental health treatment.
Dec 11, 2004, 18:16